Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Sagard Healthcare Royalty Partners
investment firm
About
Sagard Healthcare Royalty Partners is the royalty investment unit of private-equity firm of Sagard Holdings.
Highlights
Details
- Operating Status
- Active
- Investor Type
- PE
Funds Raised
| Announced Date | Fund Name | Money Raised | |
|---|---|---|---|
| Jan 10, 2020 | Fund I | $475M |
Investments
Number of Investments
Number of Lead Investments
3
2
Sagard Healthcare Royalty Partners has made 3 investments. Their most recent investment was on
Nov 1, 2022, when Phathom Pharmaceuticals raised $40M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Nov 1, 2022
Phathom Pharmaceuticals
|
Post-IPO Debt | $40M | Biotechnology | — |
|
Oct 31, 2022
Marinus Pharmaceuticals
|
Post-IPO Debt | $32.50M | Biopharma | Yes |
|
Aug 2, 2022
Valeo Pharma
|
Post-IPO Debt | $40M | Biotechnology | Yes |
Exits
Sagard Healthcare Royalty Partners has had 3 exits. Sagard Healthcare Royalty Partners most notable exits include Phathom Pharmaceuticals , Valeo Pharma
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Oct 24, 2019 | Phathom Pharmaceuticals | IPO | Biotechnology | Detail |
| Feb 22, 2019 | Valeo Pharma | IPO | Biotechnology | Detail |
| Jul 21, 2014 | Marinus Pharmaceuticals | IPO | Biopharma | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
